



BURJEEL
HOLDINGS

Full-Year 2025 Preliminary Financial Results

10 February 2026



Dr. Shamsheer Vayalil
Chairman & CEO,
Burjeel Holdings

Leadership Message

"2025 was a year of strong momentum for Burjeel Holdings, driven by an integrated network, complemented with differentiated centers of excellence, and close alignment with national healthcare priorities. Investments in our ecosystem, medical leadership, and people translated into robust growth and improved earnings quality as demand for complex care continued to rise.

During the year, we delivered regional breakthroughs in oncology, expanded women's health and orthopedics surgery programs, and accelerated progress in research, clinical trials, and medical education, reinforcing Burjeel Holdings' position as a trusted destination for super-specialty care in the Gulf.

We also expanded our footprint on schedule, scaling our community-care network in the UAE, progressing specialized care platforms in Saudi Arabia, and growing our operations and management portfolio beyond the region.

Looking ahead, supported by strong market and company fundamentals, disciplined execution, and an experienced leadership team, we are well positioned to deliver sustainable long-term value for shareholders while elevating access to high-quality healthcare across the markets we serve."

FY 2025 Highlights

Revenue

⬆️ **AED 5,501_m**
+9.8%

Patient Footfall

⬆️ **7.0 million**
+8.4%

EBITDA

⬆️ **AED 1,089_m**
+19.9%

Net Profit

⬆️ **AED 503_m**
+39.5%

Preliminary Financial Results

Income Statement Summary

AED, millions	Q4 2025 Un-audited	Q4 2024 Audited	Change, %	FY 2025 Un-audited	FY 2024 Audited	Change, %
Revenue	1,403	1,305	+7.5%	5,501	5,010	+9.8%
EBITDA	282	208	+35.4%	1,089	908	+19.9%
EBITDA Margin, %	20.1%	15.9%	+4.1 p.p.	19.8%	18.1%	+1.7 p.p.
Net Profit	141	54	+159.9%	503	360	+39.5%
Net Profit Margin, %	10.0%	4.1%	+5.9 p.p.	9.1%	7.2%	+1.9 p.p.
Earnings per Share	0.02	0.01	+159.9%	0.09	0.07	+39.5%

Balance Sheet Summary

AED, millions	31 December 2025 Un-audited	31 December 2024 Audited
Total Assets	6,657	5,879
Cash & Bank Balances	281	238
Other Assets	6,376	5,641
Total Liabilities	4,492	4,036
Interest-bearing loans and borrowings	1,918	1,208
Other Liabilities	2,574	2,828
Total Equity	2,165	1,842

Key Operational Metrics

	Q4 2025	Q4 2024	Change, %	FY 2025	FY 2024	Change, %
Outpatient						
Outpatient footfall, k	1,884	1,690	+11.5%	6,864	6,337	+8.3%
Outpatient utilization, %	73%	69%	+4.1 p.p.	67%	69%	(1.3 p.p.)
Inpatient						
Inpatient footfall, k	48	44	+9.8%	182	163	+11.7%
Bed occupancy, %	70%	70%	(0.7 p.p.)	67%	67%	+0.5 p.p.

Note: These results may differ from the audited consolidated financial statements of the Group, as these numbers will be subjected to an external audit. Amounts reported in millions are calculated based on the actual amounts. Thus, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. EBITDA is calculated as profit for the period before income tax expense, finance costs, depreciation & amortization and interest income from related parties.

Built on Strength, Delivering on Guidance

Group EBITDA

 **35.4%**
Q4'25 YoY

EBITDA Margin

20.1% +4.1 p.p.
Q4'25

Group EBITDA

 **19.9%**
FY'25 YoY

EBITDA Margin

19.8% +1.7 p.p.
FY'25

Net Profit

 **159.9%**
Q4'25 YoY

Net Profit Margin

10.0% +5.9 p.p.
Q4'25

Burjeel Holdings delivered robust revenue of AED 5,501 million in FY'25, representing a 9.8% increase, with total patient visits exceeding 7 million, up 8.4% YoY. This performance reflects strong network positioning, patient volume growth outpacing regional population trends, and resilient demand despite the temporary suspension of access related to a leading insurance provider and regulatory changes, including the Unified Procurement Program (UPP).

Revenue growth in Q4'24 reached 7.5%, rising to AED 1,403 million, alongside patient footfall growth of 11.4%, underscoring deeper community reach through the delivery of specialized products and services aligned with local market demand, supported by disciplined execution and the continued ramp-up of newly launched facilities.

Temporary access restrictions introduced across the Burjeel-branded network in May 2025 for a major Abu Dhabi-based insurer were fully resolved by 1 November 2025. Despite short-term moderation in the basic segment, strong demand from premium and self-pay patients supported performance, with patient footfall showing a strong recovery by year-end.

Inpatient volumes grew 11.7% in FY'25 and 9.8% in Q4'25, demonstrating robust demand across key specialties, including oncology, cardiology, gastroenterology, and orthopedics. More than 89,700 surgeries were performed in FY'25 led by Burjeel Medical City, Medeor Hospital Abu Dhabi, Burjeel Hospital Abu Dhabi and Lifecare Musaffah.

Outpatient footfall increased 8.3% in FY'25 and 11.5% in Q4'25, underpinned by continued market penetration and expansion of the Group's ambulatory network, notably through the ramp-up of new day care, medical, IVF, and physiotherapy centers.

EBITDA increased 35.4% to AED 282 million in Q4'25, with the margin expanding to 20.1% from 15.9% in Q4'24. The improvement was entirely operational, supported by efficient workforce planning, stronger procurement discipline, optimized supplier terms, tighter overhead cost control, and increased operating leverage from ramped-up and maturing assets.

As a result, FY'25 EBITDA rose 19.9% to AED 1,089 million, with the EBITDA margin improving to 19.8% from 18.1% in FY'24.


Net profit surged to AED 141 million in Q4'25, up 159.9% YoY, with the net margin rising to 10.0% from 4.1% in Q4'24. The increase reflected operating leverage and slower growth in non-operating costs relative to revenue.

For FY'25, net profit rose 39.5% to AED 503 million, with the net margin strengthening to 9.1%, demonstrating sustained earnings momentum.

The Group maintains a healthy balance sheet, with net leverage of 1.8x as of 31 December 2025, reflecting disciplined growth CAPEX supporting network expansion.

General Information

Name of the Company		Burjeel Holdings PLC
Date of Establishment		7 January 2020
Paid-up Capital		AED 520,513,417
Subscribed Capital		AED 520,513,417
Authorized Capital		AED 550,000,000
Chairman on Board		Dr. Shamsheer Vayalil Parambath
Vice Chairman		Mr. Saif Sultan Zayed Alfalahi
CEO		Dr. Shamsheer Vayalil
External Auditor		Ernst & Young Middle East
Mailing Address	402-DO2, 15 th floor, Al Sarab Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates	
Telephone		+971 2 304 1111
Email		info@burjeelholdings.com



Dr. Shamsheer Vayalil
Chairman & Chief Executive Officer,
Burjeel Holdings

FY 2025 Audited Financial Results (Webcast)

Date

Thursday,
5 March 2026

Time

4:00 pm Gulf Standard
Time (GST)

Please find the details
of the conference call below

[Webcast Link](#)

Conference Call Information

800 0320690

United Arab Emirates

+44 203 984 9844

United Kingdom

+1 718 866 4614

United States

For additional global dial-in numbers,
[please see the full list here](#)

Access Code:
305568

About Burjeel Holdings

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups.

As of 31 December 2025, Burjeel Holdings operates 115 assets across the UAE, Oman, and Saudi Arabia, supported by 1,784 beds and 1,776 physicians. The network includes 20 hospitals, 39 medical centers, 30 physiotherapy and wellness centers, 15 pharmacies, and 11 other allied services. The Group's portfolio of brands includes Burjeel, Medeor, LLH, Lifecare, PhysioTherabia, Alkalma, and Tajmeel.

IR Contacts

Sergei Levitskii

Director of Investor Relations

✉ sergei.levitskii@burjeelholdings.com

✉ ir@burjeelholdings.com

PO Box: 7400, Abu Dhabi, UAE

T: +971 2 3041 111

F: +971 2 2222 363

M: +971 503 802 383